T. Rowe Price Associates
ATOS icon

T. Rowe Price Associates’s Atossa Therapeutics ATOS Stock Holding History

T. Rowe Price Associates’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,413
Closed -$35K – 3067
2025
Q1 		$35K Hold
3,413
– – ﹤0.01% 2967
2024
Q4 		$49K Buy
3,413
+695
+26% +$13.6K ﹤0.01% 2943
2024
Q3 		$62K Hold
2,718
– – ﹤0.01% 2902
2024
Q2 		$0 Buy
+2,718
New +$60.1K ﹤0.01% 2930
2022
Q4 		– Sell
-2,293
Closed -$29K – 2937
2022
Q3 		$29K Hold
2,293
– – ﹤0.01% 2890
2022
Q2 		$37K Sell
2,293
-683
-23% -$10.8K ﹤0.01% 2893
2022
Q1 		$56K Buy
2,976
+1,320
+80% +$26.8K ﹤0.01% 2913
2021
Q4 		$40K Sell
1,656
-180
-10% -$6.59K ﹤0.01% 2934
2021
Q3 		$90K Buy
1,836
+180
+11% +$10.5K ﹤0.01% 2860
2021
Q2 		$157K Buy
+1,656
New +$87.7K ﹤0.01% 2772

Other funds holding ATOS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

T. Rowe Price Associates's ATOS Position: Q2 2025 in Review

T. Rowe Price Associates sold out of Atossa Therapeutics (ATOS) in Q2 2025, closing a stake of 3,413 shares — an estimated $35K sold.

T. Rowe Price Associates first reported a position in ATOS in Q2 2021 and held it in 10 quarters. The position peaked at $157K in Q2 2021. 84 funds tracked by Wall St. Rank hold ATOS as of Q2 2025.

  • T. Rowe Price Associates reported no remaining Atossa Therapeutics position as of Q2 2025 after selling out during the quarter.
  • T. Rowe Price Associates sold 3,413 Atossa Therapeutics shares in Q2 2025, an estimated $35K.
  • T. Rowe Price Associates first reported a position in Atossa Therapeutics in Q2 2021 and held it in 10 quarters.
  • T. Rowe Price Associates's Atossa Therapeutics position peaked at $157K in Q2 2021.
  • 84 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q2 2025.

Based on T. Rowe Price Associates's 13F filing for Q2 2025, filed 14 Aug 2025.